InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,522.30
(
1.58%
)
US TECH 100
18,870.40
(
0.15%
)
Dow Jones
40,842.79
(
0.24%
)
Brent Oil
81.56
(
0.06%
)
Bitcoin
64,512.30
(
-0.13%
)
Post# of 475
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

INFINITI

Send PM Follow Ignore
Followers 171
Posts 22574
Boards Moderated 0
Alias Born 11/01/2012

INFINITI

Re: None

Wednesday, 08/30/2023 11:33:07 AM

Wednesday, August 30, 2023 11:33:07 AM

Post# of 475

Axcella currently has a Zacks Rank #2 (Buy).

Some other top-ranked stocks in the pharma/biotech sector worth mentioning are J&J JNJ, Corcept Therapeutics CORT and Dynavax Technologies DVAX, each carrying a Zacks Rank #2 at present.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

In the past 30 days, the Zacks Consensus Estimate for J&J’s 2023 earnings per share has increased from $10.73 to $10.75. During the same period, the estimate for JNJ’s 2024 earnings per share has increased from $11.28 to $11.30. Year to date, shares of JNJ have lost 7%.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up